Catalysts for $NVS
563 tracked
Oct 31, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Oct 6, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Oct 6, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Sep 28, 2023
approval
SANDIMMUNE (CYCLOSPORINE) — FDA approval
Restasis
→
Sep 28, 2023
approval
SANDIMMUNE (CYCLOSPORINE) — FDA approval
Restasis
→
Sep 28, 2023
approval
SANDIMMUNE (CYCLOSPORINE) — FDA approval
Restasis
→
Sep 13, 2023
approval
TEGRETOL (CARBAMAZEPINE) — FDA approval
carbamazepine ER
→
Sep 13, 2023
approval
TEGRETOL (CARBAMAZEPINE) — FDA approval
carbamazepine ER
→
Sep 13, 2023
approval
TEGRETOL-XR (CARBAMAZEPINE) — FDA approval
carbamazepine ER
→
Aug 31, 2023
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Aug 31, 2023
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jul 24, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Jul 24, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Jul 24, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Jul 7, 2023
approval
LEQVIO (INCLISIRAN SODIUM) — FDA approval
inclisiran
→
Jun 26, 2023
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
May 26, 2023
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
May 26, 2023
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
May 11, 2023
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Mar 16, 2023
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 16, 2023
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 16, 2023
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 16, 2023
approval
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Mar 7, 2023
approval
ZOLEDRONIC ACID — FDA approval
NOVARTIS AG
→
Feb 17, 2023
approval
LEQVIO (INCLISIRAN SODIUM) — FDA approval
inclisiran
→
Oct 12, 2022
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Sep 2, 2022
approval
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 19, 2022
approval
GLEEVEC (IMATINIB MESYLATE) — FDA approval
Imatinib Mesylate Shilpa
→
Jun 22, 2022
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jun 22, 2022
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→